(2026). Clopidogrel, an ADP‐P2Y12 Receptor Antagonist, Is Associated With Lower Opioid Consumption and a Reduced Incidence of Delirium in Cancer Patients Receiving Chemotherapy: A Nationwide Retrospective Cohort Study in Japan. Neuropsychopharmacology Reports.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Clopidogrel, an ADP‐P2Y12 Receptor Antagonist, Is Associated With Lower Opioid Consumption and a Reduced Incidence of Delirium in Cancer Patients Receiving Chemotherapy: A Nationwide Retrospective Cohort Study in Japan."
Neuropsychopharmacology Reports 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Clopidogrel, an ADP‐P2Y12 Receptor Antagonist, Is Associated With Lower Opioid Consumption and a Reduced Incidence of Delirium in Cancer Patients Receiving Chemotherapy: A Nationwide Retrospective Cohort Study in Japan."
Neuropsychopharmacology Reports, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.